Co-pay accumulator adjustment programs can have different effects for individuals with varying health plan types or income levels, explained Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Co-pay accumulator adjustment programs can have different effects for individuals with varying health plan types or income levels, explained Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
How might co-pay accumulator adjustment programs disproportionately affect certain populations?
From an insurance standpoint, the co-pay accumulator programs really are only in effect for individuals enrolled in a high-deductible, consumer-directed health plan. So, individuals who are in PPO [preferred provider organization] plans typically don’t have the high deductible with the pharmacy benefit that individuals have who are enrolled in a high-deductible health plan, where typically the deductible is a combined medical and pharmacy benefit.
That’s one consideration; the other concern is income, and the fact that there’s some evidence to suggest that low-income individuals, who are more price-sensitive to access to and use of healthcare, might preferentially select a high-deductible health plan simply because it provides them with more money in their pocket because of lower premiums, but at the expense of a high deductible. And they are probably the ones who would be at greatest risk of discontinuation of medication when faced with this so-called “co-pay surprise” when they’ve maximized the value derived from their co-pay support but haven’t yet met their deductible because of the co-pay accumulator adjustment program.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Cost Barriers Continue to Limit Access to Fertility Care
October 24th 2024Of the 10% of women contacted for this survey who said that they or their partner had ever sought fertility assistance, only 7% were able to get the necessary care; cost was cited as the top reason for not being able to access fertility services.
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More